Shaonan Liu

Shaonan Liu

Auto-generated profile, based on publicly available information

Shaonan Liu

Guangdong Provincial Hospital of Chinese Medicine

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
SLShaonan Liu
Shaonan Liu
JSJohannah Shergis
Johannah Shergis
XCXiankun Chen
Xiankun Chen
XYXuhua Yu
Xuhua Yu
XGXinfeng Guo
Xinfeng Guo
CXCharlie Changli Xue
Charlie Changli Xue
Objective. To evaluate the efficacy and safety of Weijing decoction combined with routine pharmacotherapy (RP) for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Methods. Randomized controlled trials (RCT) evaluating Weijing decoction for AECOPD were included. English, Chinese, and Japanese databases were searched from their respective inceptions to June 2013. The methodological quality was assessed according to the Cochrane Collaboration’s risk of bias tool. All data were analyzed and synthesized using RevMan 5.2 software. Results. Fifteen (15) studies involving 986 participants were included. Participants were diagnosed with COPD in the acute exacerbation stage. In addition, most of studies reported that they included participants with the Chinese medicine syndrome, phlegm‐heat obstructing the Lung. Weijing decoction combined with RP improved lung function (forced expiratory volume in one second; FEV1), arterial blood gases (PaO2 and PaCO2), clinical effective rate, and reduced inflammatory biomarkers (TNF‐α and IL‐8) when compared with RP alone. No severe adverse events were reported in these studies. Conclusions. Weijing decoction appeared to be beneficial for AECOPD and well‐tolerated when taken concurrently with RP, such as antibiotics, bronchodilators (oral and inhaled), and mucolytics.

1 January 2016 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
LWLei Wang
Lei Wang
XZXujie Zhao
Xujie Zhao
SMShuai Mao
Shuai Mao
SLShaonan Liu
Shaonan Liu
XGXinfeng Guo
Xinfeng Guo
MZMinzhou Zhang
Minzhou Zhang
This study seeks to investigate potential cardioprotection of Danlou Tablets in patients undergoing PCI with non‐ST elevation acute coronary syndrome (NSTE‐ACS). 219 patients with NSTE‐ACS were randomised to Danlou Tablet pretreatment (n = 109) or placebo (n = 110). No patients received statins prior to PCI and all patients were given atorvastatin (10 mg/day) after procedure. The main endpoint was the composite incidence of major adverse cardiac events (MACEs) within 30 days after PCI. The proportion of patients with elevated levels of cTn I>5 × 99% of upper reference limit was significantly lower in the Danlou Tablet group at 8 h (22.0% versus 34.5%, p = 0.04) and 24 h (23.9% versus 38.2%, p = 0.02) after PCI. The 30‐day MACEs occurred in 22.0% of the Danlou Tablet group and 33.6% in the placebo group (p = 0.06). The incidence of MACE at 90‐day follow‐up was significantly decreased in the Danlou Tablet group compared to the placebo group (23.9% versus 37.3%, p = 0.03). The difference between the groups at 90 days was the incidence of nonfatal myocardial infarction (22% versus 34.5%, p = 0.04). These findings might support that treatment with Danlou Tablet could reduce the incidence of periprocedural myocardial infarction in patients with ACS undergoing PCI.

1 January 2015 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
MCMeaghan Coyle
Meaghan Coyle
JSJohannah Linda Shergis
Johannah Linda Shergis
SLShaonan Liu
Shaonan Liu
LWLei Wu
Lei Wu
AZAnthony Lin Zhang
Anthony Lin Zhang
CXCharlie Changli Xue
Charlie Changli Xue
Chinese herbal medicine (CHM) is increasingly used by patients with chronic obstructive pulmonary disease (COPD); however, there has been no systematic evaluation of its safety. This review examined the adverse events (AEs) reported in clinical studies of CHM for COPD. Five English databases (PubMed, Embase, CINAHL, AMED, and CENTRAL) and four Chinese databases (CBM, CNKI, CQVIP, and Wanfang Data) were searched from inception to May 2013. Adverse event data, including nature, severity, author-assigned causality, management, and outcome, were extracted from included studies. Descriptive statistics were used for the rate of adverse events. Of the 152 included studies, AEs were reported in 47 studies. The rate of adverse events was slightly lower in the CHM groups compared with controls (84 events in 5,909 participants, 1.4% versus 102 events in 5,676 participants, 1.8%). The most frequently reported adverse event was nausea (28 cases in the CHM groups and 19 cases in the control groups), which was more common in studies where CHM was combined with pharmacotherapy to treat acute exacerbation of COPD. Other frequent adverse events were abdominal discomfort, dry mouth, and dizziness. Detailed information about the adverse events was scant. Overall, CHM appears to be well tolerated in people with COPD.

1 January 2020 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
QXQianwen Xie
Qianwen Xie
XDXueyi Deng
Xueyi Deng
JXJingmin Xiao
Jingmin Xiao
XCXueyin Chen
Xueyin Chen
YHYihan He
Yihan He
XGXinfeng Guo
Xinfeng Guo
Background. Ischemic stroke (IS) seriously impacts the quality of life of survivors. Chinese medicine (CM) has been developed for more than 2000 years and plays a key role in the treatment of ischemic stroke. Many Chinese medicine clinical trials have been conducted; however, the heterogeneity of outcome measurements and reporting limits implications of the findings in clinical practice and health policy development. Therefore, it is important to develop a core outcome set (COS) that should be used and reported in trials for ischemic stroke treated by Chinese medicine. This protocol describes the process of developing the IS‐CM‐COS. Methods and Analysis. The development of the COS will involve the following four steps: (1) A list of outcomes reported in the registered and published Chinese medicine trials of ischemic stroke will be extracted by conducting a systematic literature review. (2) An additional outcome list will be collected by semistructured interview to patients with ischemic stroke. (3) A two‐round Delphi survey will be performed to prioritize and condense the outcomes. (4) In the consensus meeting, a final recommended COS will be developed. Discussion. The COS could improve the reliability and consistency of outcome reporting. We hope that this IS‐CM‐COS will be used in the future Chinese medicine trials for the treatment of ischemic stroke and improve research quality. Trial Registration. This study was registered with the Core Outcome Measures in Effectiveness Trials Initiative (http://www.comet-initiative.org/studies/details/1282).

8 September 2015 in European Journal of Integrative Medicine
Verified
Journal Article
Closed access
MCMeaghan E. Coyle
Meaghan E. Coyle
SLShaonan Liu
Shaonan Liu
AZAnthony Lin Zhang
Anthony Lin Zhang
CXCharlie Changli Xue
Charlie Changli Xue

1 September 2012
Verified
Journal Article
Closed access
XGXin-Feng Guo
Xin-Feng Guo
ZWZehuai Wen
Zehuai Wen
YXYan-Ming Xie
Yan-Ming Xie
SLShao-Nan Liu
Shao-Nan Liu
ZLZhen-Yu Li
Zhen-Yu Li
DCDa-Can Chen
Da-Can Chen